TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36143102
Drug: Both antiplatelets
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both antiplatelets and oral anticoagulation
Study: 36143388
Drug: Continuous amnioinfusion
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous amnioinfusion with Amnion Flush Solution (up to 100 mL/h, 2400 mL/day)
Study: 36143388
Drug: Standard PPROM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PPROM therapy (antibiotics and corticosteroids)
Study: 37928895
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus chemotherapy (NC)
Study: 36149737
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) for 6 weeks
Study: 36149832
Drug: Darvadstrocel (24-mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darvadstrocel (24-mL intralesional injection, 120×106 cells)
Study: 36150050
Drug: Enasidenib 100mg
Normalized name: ENASIDENIB 100MG TAB
DrugBank: Enasidenib (DB13874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enasidenib 100mg daily
Study: 36150050
Drug: Enasidenib maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enasidenib maintenance therapy
Study: 36150143
Drug: Valemetostat 200
Normalized name: tazemetostat 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valemetostat 200 mg/day orally until progressive disease or unacceptable toxicity
Study: 36150668
Drug: SARS-CoV-2 vaccine
Normalized name: SARS-CoV-2 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 vaccine (CoronaVac) administered in two doses (28-days interval) with a booster at day 210.
Study: 38609322
Drug: TNF inhibitors
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF inhibitors (TNFi)
Study: 36150668
Drug: SSZ+TNFi combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSZ+TNFi combination
Study: 36150668
Drug: Third dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third dose of vaccine (D69-D240)
Study: 36151335
Drug: Appropriate empiric
Normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate empiric therapy
Study: 36151773
Drug: Metformin in
Normalized name: Product containing metformin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin in combination with VIT (vincristine, irinotecan, and temozolomide) at Dose Level 4 (1666 mg/m2)
Study: 36151773
Drug: Metformin in
Normalized name: Product containing metformin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin in combination with VIT
Study: 36152144
Drug: Ribociclib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib (600 mg/day, 3 weeks on/1 week off) plus letrozole (2.5 mg/day)
Study: 36152902
Drug: Thoracic Spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic Spinal Nerve Neuromodulation Therapy
Study: 36152897
Drug: Anti-tumor necrosis
Normalized name: G 1 (anti-tumor agent)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tumor necrosis factor agents
Study: 36155150
Drug: Plasma l-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma l-carnitine
Study: 36155150
Drug: Plasma l-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma l-carnitine (highest tertile)
Study: 36155490
Drug: Antiangiogenic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiangiogenic agents (sorafenib, lenvatinib, regorafenib, cabozantinib, ramucirumab)
Study: 36155490
Drug: Chemotherapy based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy based regimens
Study: 36155490
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with anti-PD-1/PD-L1 or anti-CTLA4 antibodies
Study: 36156099
Drug: Epacadostat 100
Normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epacadostat 100 mg orally twice daily with pembrolizumab 200 mg intravenously every 3 weeks and one of 7 chemotherapy regimens
Study: 36156099
Drug: Epacadostat 100
Normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epacadostat 100 mg orally twice daily with pembrolizumab and chemotherapy
Study: 36158588
Drug: Selective internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective internal radiation therapy with resin yttrium-90 microspheres (SIRT) followed by gemcitabine 1,000 mg/m²
Study: 36158690
Drug: Cytokine-induced killer
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cytokine-induced killer (CIK) cells combined with cytotoxic chemotherapy (etoposide plus platinum) followed by sintilimab maintenance treatment
Study: 36158690
Drug: Sintilimab maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab maintenance treatment
Study: 36161320
Drug: lovo-cel gene
Normalized name: Lovo-cel
DrugBank: Lovotibeglogene autotemcel (DB18680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lovo-cel gene therapy (bb1111; LentiGlobin)
Study: 36710205
Drug: Short-term androgen
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term androgen deprivation therapy (ADT)
Study: 36162011
Drug: CMV-specific immunoglobulins
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV-specific immunoglobulins (CMV-Ig) administered to 10 patients in addition to standard antiviral prophylaxis.
Study: 36162011
Drug: Standard antiviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiviral prophylaxis without CMV-Ig administered to 39 patients.
Study: 36163163
Drug: Weekly carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly carboplatin (area under the curve 2) and weekly paclitaxel 80 mg/m2 in cohort 1 (triple-negative)
Study: 36163163
Drug: Cyclophosphamide and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide and/or paclitaxel in cohort 2 (hormone receptor-positive)
Study: 36164334
Drug: Ivermectin nanosuspension
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin nanosuspension mucoadhesive nasal spray (two puffs per day)
Study: 36164935
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan (T-DXd) at 6.4 mg/kg administered intravenously on day 1 of each 21-day cycle
Study: 36165055
Drug: Mesalazine (Pentasa)
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine (Pentasa) treatment
Study: 36165893
Drug: FAK inhibition
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAK inhibition (defactinib) in combination with stereotactic body radiotherapy (RT)
Study: 36165893
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of RT and FAK inhibition with checkpoint immunotherapy
Study: 36166287
Drug: Care ally-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care ally-assisted massage (3.5-hour training workshop, instructional DVD, printed treatment manual, three 30-minute at-home sessions weekly for 3 months)
Study: 36166287
Drug: Therapist-treated massage
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-treated massage (two 60-minute sessions tailored to individual pain experiences and treatments per week for 3 months)
Study: 36166340
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulants (DOAC) with dual or triple antiplatelet therapy
Study: 36166340
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonists (warfarin) with corresponding strategies
Study: 36166340
Drug: Dual antithrombotic
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antithrombotic therapy
Study: 36166648
Drug: Artificial intelligence-driven
Normalized name: Intelence
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artificial intelligence-driven digital health solution for self-management and clinical decision support
Study: 36167584
Drug: Interprofessional medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interprofessional medication adherence intervention led by pharmacists, combining motivational interviews and feedback with electronic monitor (EM) drug assessment.
Study: 36167894
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine (HiDAC) with median dosage of 17.6 g/m (IQR 16.5-18.0)
Study: 36167894
Drug: Intermediate-dose cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermediate-dose cytarabine (IDAC)
Study: 39141673
Drug: Inhaled Nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Nitric Oxide
Study: 36169998
Drug: Gameplay data
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gameplay data analysis using state-of-the-art ML algorithms
Study: 36170017
Drug: Early intensified
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intensified treatment
Study: 36170501
Drug: GPRC5D-targeted CAR
Normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPRC5D-targeted CAR T-cell therapy (MCARH109) at a maximum tolerated dose of 150×10^6 cells.
Study: 36170815
Drug: NADPH oxidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: NADPH oxidase inhibitor apocynin
Study: 36171508
Drug: Low SVCF
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low SVCF < 55 ml/kg/min
Study: 36171508
Drug: Combined use
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined use of low SVCF < 55 ml/kg/min and ACA-RI > 0.75
Study: 36171508
Drug: Combined metrics
Normalized name: Polistes metricus venom protein
DrugBank: Polistes metricus venom protein (DB11029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined metrics using cut-off value of < 41 ml/kg/min for SVCF and > 0.85 for ACA-RI
Study: 36172030
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis (IVT) with alteplase
Study: 36172138
Drug: Infliximab (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (single dose infusion)
Study: 36172517
Drug: Swedish quality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swedish quality register for systematic data collection from patients receiving treatment for gambling disorder.
Study: 36172964
Drug: Spironolactone prescription
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone prescription in ideal patients
Study: 36172964
Drug: Spironolactone prescription
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone prescription in contraindicated patients
Study: 36175821
Drug: 1% atropine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% atropine weekly tapered to 0.01% atropine daily at 6 months
Study: 36175821
Drug: 0.01% atropine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% atropine daily for 1 year
Study: 36175948
Drug: Broad-spectrum antimicrobial
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum antimicrobial therapy for more than 72 hours
Study: 36175948
Drug: Narrow-spectrum antimicrobial
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-spectrum antimicrobial therapy (less than 72 hours)
Study: 36178485
Drug: PCSK9i receivers
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCSK9i receivers (ongoing treatment with evolocumab 140 mg, n=632, 38.1% of total)
Study: 36178485
Drug: PCSK9i receivers
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCSK9i receivers (ongoing treatment)
Study: 36178583
Drug: Etanercept treatment
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept treatment adherence after 1 year
Study: 36178583
Drug: Etanercept treatment
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept treatment adherence after 7 years
Study: 36179090
Drug: Wearable sensors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wearable sensors during 1 week of unsupervised daily-living monitoring
Study: 36179090
Drug: In-home off-medication
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-home off-medication testing
Study: 36179090
Drug: In-home on-medication
Normalized name: selenium sulfide
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-home on-medication testing
Study: 36179488
Drug: Dose and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose and volume de-escalated intensity-modulated radiation therapy (IMRT) after two cycles of induction chemotherapy with docetaxel 60 mg/m².
Study: 36179736
Drug: Oral fexinidazole
Normalized name: fexinidazole
DrugBank: Fexinidazole (DB12265)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fexinidazole (1200 mg for 20-34 kg; 1800 mg for 35 kg or more) once per day for 4 days, followed by 600 mg or 1200 mg once per day for 6 days.
Study: 36180114
Drug: Self-administered questionnaires
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered questionnaires for sleep disorders
Study: 36180329
Drug: Ixazomib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib monotherapy
Study: 36180329
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (ixazomib monotherapy and ixazomib plus rituximab)
Study: 36180844
Drug: Machine Learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine Learning (ML) algorithms for classification
Study: 36181587
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy group (CPT)
Study: 36182027
Drug: Brief Behavioral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Behavioral Therapy for Insomnia (BBTI)
Study: 36182805
Drug: Proxalutamide 200
Normalized name: Proxalutamide
DrugBank: Proxalutamide (DB16065)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proxalutamide 200 mg/day
Study: 36182805
Drug: Proxalutamide 200
Normalized name: Proxalutamide
DrugBank: Proxalutamide (DB16065)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proxalutamide 200 mg/day in triple-negative subgroup
Study: 36183100
Drug: Monthly screening
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly screening using ultrasensitive rapid diagnostic tests and treatment with dihydroartemisinin-piperaquine (DHA-PQ)
Study: 36183444
Drug: Arfolitixorin (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arfolitixorin (30, 60, 120, or 240 mg/m) combined with 5-fluorouracil (5-FU)
Study: 36183869
Drug: Access to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Access to antibody testing
Study: 36184067
Drug: Lorlatinib (detailed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib (detailed dosage and duration not specified)
Study: 36184642
Drug: Camrelizumab 200
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab 200 mg + Apatinib 500 mg + Fuzuloparib 100 mg
Study: 36185311
Drug: Nanotechnology-enhanced immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanotechnology-enhanced immunotherapy combined with ferroptosis; specific dosage and duration not mentioned.
Study: 36185706
Drug: Intravenous difelikefalin
Normalized name: difelikefalin
DrugBank: Difelikefalin (DB11938)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous difelikefalin 0.5 μg/kg after each hemodialysis session for 12 weeks
Study: 36185969
Drug: Homologous vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homologous vaccination (three doses of BNT162b2) followed by BNT162b2 booster
Study: 36185969
Drug: Heterologous vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heterologous vaccination (two doses of CoronaVac followed by BNT162b2 booster)
Study: 36186648
Drug: BNT162b2 mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 mRNA vaccine administration to convalescent mothers
Study: 36186721
Drug: Riociguat (0.5-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riociguat (0.5-2.5 mg three times daily, based on bodyweight)
Study: 36186794
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 6 mL/kg
Study: 36186794
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 8 mL/kg
Study: 36186794
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 10 mL/kg
Study: 36186794
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 12 mL/kg
Study: 36186810
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine ointment applied twice daily for 2 weeks
Study: 36186856
Drug: Mindfulness-based group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based group therapy (Feel-Good intervention), 8 sessions over 8 weeks.
Study: 36186962
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IASBPD and PVR-derived parameters
Study: 36188406
Drug: DHA +
Normalized name: PNV-DHA + Docusate Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA + EPA supplementation (2.442 g/day DHA and 1.020 g/day EPA)
Study: 36188867
Drug: Repetitive Transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) combined with Video Game-Based Training, details on dosage and duration not available
Study: 36188946
Drug: Functional Electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional Electrical Stimulation (FES) therapy delivered by the MyndMove stimulator, 40 sessions
Study: 36189149
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg hydroxyzine plus 0.5 mg/kg midazolam
Study: 36189149
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg hydroxyzine plus 0.5 mg/kg midazolam
Study: 36189149
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg midazolam alone
Study: 36189908
Drug: Primary dental
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary dental care (PDC) treatment
Study: 36190737
Drug: Oral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paracetamol 1000 mg × 4 + oral ibuprofen 400 mg × 4 + intravenous placebo
Study: 36190737
Drug: Oral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paracetamol 1000 mg × 4 + intravenous dexamethasone 24 mg + oral placebo
Study: 36190737
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen 400 mg × 4 + intravenous dexamethasone 24 mg + oral placebo
Study: 36190737
Drug: Oral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paracetamol 1000 mg × 4 + oral ibuprofen 400 mg × 4 + intravenous dexamethasone 24 mg
Study: 36190744
Drug: Chronolife smart
Normalized name: benzalkonium chloride Topical Foam [Smart San]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronolife smart t-shirt worn daily for 2 weeks (preferably 8 hours per day)
Study: 36190739
Drug: H2 antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: H2 antagonists (nizatidine, famotidine, ranitidine)
Study: 36190739
Drug: Monoamine modulators
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoamine modulators (reboxetine, fluoxetine)
Study: 36190739
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or no treatment (standard care)
Study: 36192231
Drug: Ovulation Induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovulation Induction (OI) or No Treatment
Study: 36192514
Drug: Combination intra-peritoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination intra-peritoneal and systemic chemotherapy
Study: 36194670
Drug: Camrelizumab (CC)
Normalized name: Ocrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab (CC)
Study: 36194670
Drug: Chemotherapy (CA)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CA)
Study: 36194864
Drug: Low-dose multiplayer
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose multiplayer virtual reality telegaming program (2 supervised 1-hour sessions per week for 1 month)
Study: 36195441
Drug: Intravenous infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infliximab (IFX) 3 mg/kg
Study: 36195441
Drug: Intravenous infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infliximab (IFX)
Study: 36196060
Drug: Time-to-diuretics (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-to-diuretics (intravenous furosemide) administered within the first 24 hours, median time 67 minutes (25th-75th percentiles 17-190 minutes)